Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Shao, Zhimin; Pang, Da; Yang, Hongjian; Li, Wěi; Wang, Shusen; Cui, Shude; Liao, Ning; Wang, Yongsheng; Wang, Chuan; Chang, Yuan-Ching; Wang, Hweichung; Yun Kang, Seok; Hong Seo, Jae; Shen, Kunwei; Laohawiriyakamol, Suphawat; Jiang, Zefei; Li, Junjie; Q. Zhou, Julian; Althaus, Betsy; Mao, Yixiang; Eng‐Wong, Jennifer

doi:10.1001/jamaoncol.2019.3692

Public

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Published in JAMA Oncology • Oct 24, 2019

Authors:

Zhimin Shao

Da Pang

Hongjian Yang

Abstract

Importance: Prospective assessment of treatments known to benefit patients in global clinical trials in specific racial groups is essential. Objective: To compare the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and docetaxel vs placebo, trastuzumab, and docetaxel in Asian ...

Subject

Medicine

Pertuzumab

Trastuzumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!